KALA BIO, Inc
Price
FilingsNewest: 8-K, Material agreementSep 10 →InsidersNo open-market buys. 5 insiders sold $248,725, 0 of 6 sales on a 10b5-1 plan.→HoldersVanguard 1.1%Geode 0.8%Vanguard Fiduciary Trust 0.5%→Financing →PeersClosest companies: QTTB, PLRX, SYRE→
From the filings
Figures
- Revenue
- $0.00last 12 months
- Net income
- −$10.1Mlast 12 months
- Operating cash flow
- −$26.1Mlast 12 months
- Cash and equivalents
- $229,000at the last balance sheet
- Total debt
- $55.4Mat the last balance sheet
- Shares outstanding
- 19.3M shareson issue